



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

February 26, 2020

Via E-mail  
Taylor Harris  
Chief Financial Officer  
MyoKardia, Inc.  
333 Allerton Ave  
South San Francisco, CA 94080

**Re: MyoKardia, Inc.**  
**Form 10-Q for the quarterly period ended September 30, 2019**  
**Exhibit No. 10.1 - Termination Agreement, by and between the Registrant and**  
**Aventis, Inc. dated July 17, 2019**  
**Filed November 4, 2019**  
**File No. 001-37609**

Dear Mr. Harris:

We have concluded our assessment of your redacted exhibit for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance